929 related articles for article (PubMed ID: 32726355)
1. Interplay between SARS-CoV-2 and the type I interferon response.
Sa Ribero M; Jouvenet N; Dreux M; Nisole S
PLoS Pathog; 2020 Jul; 16(7):e1008737. PubMed ID: 32726355
[TBL] [Abstract][Full Text] [Related]
2. Harnessing the immune system to overcome cytokine storm and reduce viral load in COVID-19: a review of the phases of illness and therapeutic agents.
Khadke S; Ahmed N; Ahmed N; Ratts R; Raju S; Gallogly M; de Lima M; Sohail MR
Virol J; 2020 Oct; 17(1):154. PubMed ID: 33059711
[TBL] [Abstract][Full Text] [Related]
3. Type 1 interferons as a potential treatment against COVID-19.
Sallard E; Lescure FX; Yazdanpanah Y; Mentre F; Peiffer-Smadja N
Antiviral Res; 2020 Jun; 178():104791. PubMed ID: 32275914
[TBL] [Abstract][Full Text] [Related]
4. Compounds with Therapeutic Potential against Novel Respiratory 2019 Coronavirus.
Martinez MA
Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32152082
[TBL] [Abstract][Full Text] [Related]
5. Immunopathology and immunotherapeutic strategies in severe acute respiratory syndrome coronavirus 2 infection.
Keam S; Megawati D; Patel SK; Tiwari R; Dhama K; Harapan H
Rev Med Virol; 2020 Sep; 30(5):e2123. PubMed ID: 32648313
[TBL] [Abstract][Full Text] [Related]
6. Antiviral activities of type I interferons to SARS-CoV-2 infection.
Mantlo E; Bukreyeva N; Maruyama J; Paessler S; Huang C
Antiviral Res; 2020 Jul; 179():104811. PubMed ID: 32360182
[TBL] [Abstract][Full Text] [Related]
7. Type I and Type III Interferons Restrict SARS-CoV-2 Infection of Human Airway Epithelial Cultures.
Vanderheiden A; Ralfs P; Chirkova T; Upadhyay AA; Zimmerman MG; Bedoya S; Aoued H; Tharp GM; Pellegrini KL; Manfredi C; Sorscher E; Mainou B; Lobby JL; Kohlmeier JE; Lowen AC; Shi PY; Menachery VD; Anderson LJ; Grakoui A; Bosinger SE; Suthar MS
J Virol; 2020 Sep; 94(19):. PubMed ID: 32699094
[TBL] [Abstract][Full Text] [Related]
8. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
[TBL] [Abstract][Full Text] [Related]
9. Type I and Type III Interferons - Induction, Signaling, Evasion, and Application to Combat COVID-19.
Park A; Iwasaki A
Cell Host Microbe; 2020 Jun; 27(6):870-878. PubMed ID: 32464097
[TBL] [Abstract][Full Text] [Related]
10. Overview of Immune Response During SARS-CoV-2 Infection: Lessons From the Past.
Shah VK; Firmal P; Alam A; Ganguly D; Chattopadhyay S
Front Immunol; 2020; 11():1949. PubMed ID: 32849654
[TBL] [Abstract][Full Text] [Related]
11. Flattening the COVID-19 Curve With Natural Killer Cell Based Immunotherapies.
Market M; Angka L; Martel AB; Bastin D; Olanubi O; Tennakoon G; Boucher DM; Ng J; Ardolino M; Auer RC
Front Immunol; 2020; 11():1512. PubMed ID: 32655581
[TBL] [Abstract][Full Text] [Related]
12. Overview of lethal human coronaviruses.
Chen B; Tian EK; He B; Tian L; Han R; Wang S; Xiang Q; Zhang S; El Arnaout T; Cheng W
Signal Transduct Target Ther; 2020 Jun; 5(1):89. PubMed ID: 32533062
[TBL] [Abstract][Full Text] [Related]
13. The Role of Type I Interferons in the Pathogenesis and Treatment of COVID-19.
Schreiber G
Front Immunol; 2020; 11():595739. PubMed ID: 33117408
[TBL] [Abstract][Full Text] [Related]
14. Innate Immune Signaling and Proteolytic Pathways in the Resolution or Exacerbation of SARS-CoV-2 in Covid-19: Key Therapeutic Targets?
Sallenave JM; Guillot L
Front Immunol; 2020; 11():1229. PubMed ID: 32574272
[TBL] [Abstract][Full Text] [Related]
15. [Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Should we target the virus, the cell or the disease?].
Nisole S; Saulnier A; Gatignol A
Virologie (Montrouge); 2020 Jun; 24(3):135-141. PubMed ID: 32648548
[No Abstract] [Full Text] [Related]
16. A role for retinoids in the treatment of COVID-19?
Trasino SE
Clin Exp Pharmacol Physiol; 2020 Oct; 47(10):1765-1767. PubMed ID: 32459003
[TBL] [Abstract][Full Text] [Related]
17. Attenuated Interferon and Proinflammatory Response in SARS-CoV-2-Infected Human Dendritic Cells Is Associated With Viral Antagonism of STAT1 Phosphorylation.
Yang D; Chu H; Hou Y; Chai Y; Shuai H; Lee AC; Zhang X; Wang Y; Hu B; Huang X; Yuen TT; Cai JP; Zhou J; Yuan S; Zhang AJ; Chan JF; Yuen KY
J Infect Dis; 2020 Aug; 222(5):734-745. PubMed ID: 32563187
[TBL] [Abstract][Full Text] [Related]
18. Current pharmacological treatments for SARS-COV-2: A narrative review.
Nittari G; Pallotta G; Amenta F; Tayebati SK
Eur J Pharmacol; 2020 Sep; 882():173328. PubMed ID: 32603692
[TBL] [Abstract][Full Text] [Related]
19. SARS, MERS and SARS-CoV-2 (COVID-19) treatment: a patent review.
Nascimento Junior JAC; Santos AM; Quintans-Júnior LJ; Walker CIB; Borges LP; Serafini MR
Expert Opin Ther Pat; 2020 Aug; 30(8):567-579. PubMed ID: 32429703
[TBL] [Abstract][Full Text] [Related]
20. Evasion of Type I Interferon by SARS-CoV-2.
Xia H; Cao Z; Xie X; Zhang X; Chen JY; Wang H; Menachery VD; Rajsbaum R; Shi PY
Cell Rep; 2020 Oct; 33(1):108234. PubMed ID: 32979938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]